Muhammad Ibrar

Dr. Muhammad Ibrar


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2022 in PHYTONutrients
Verified
Journal Article
Open access
PDF file
Yaseen HussainYaseen Hussain
Yaseen Hussain
Prof. Dr. Haroon KhanProf. Dr. Haroon Khan
Prof. Dr. Haroon Khan
WAWaqas Alam
Waqas Alam
ZAZakir Ali
Zakir Ali
MIMuhammad Ibrar
Muhammad Ibrar
DIABETES mellitus is a multifactorial chronic metabolic disorder characterized by altered metabolism of macro – nutrients such fats, proteins and carbohydrates associated with disturbances in insulin activity. Diabetes mellitus complications include, diabetic retinopathy, diabetic cardiomyopathy, diabetic encephalopathy, diabetic periodontitis and diabetic nephropathy. These complications are mostly induced by inflammatory and oxidative mediators. Curcumin is a polyphenol extracted from turmeric and it is well known for its antioxidant, anti-inflammatory and antiapoptotic activities. It effectively targets oxidative mediators in diabetes mellitus through regulation of several signaling pathways. Insulin resistance is commonly caused due to impairment in the signaling pathways related to insulin and the target tissues pose lesser or no response to circulating insulin. Curcumin is a potent therapeutic agent that targets oxidative stress mediators in diabetes mellitus and its resistant version leading to favorable therapeutic outcomes in diabetes complications. This review has thrown sufficient light on the therapeutic potential of curcumin targeting oxidative mediators in diabetes and its related complications.

1 September 2025 in Food Science & Nutrition
Verified
Journal Article
Open access
JFJirui Fan
Jirui Fan
MIMuhammad Ibrar
Muhammad Ibrar
MKMir Azam Khan
Mir Azam Khan
AKAbdullah Khan
Abdullah Khan
MJMuhammad Saeed Jan
Muhammad Saeed Jan
MRMaqsood Ur Rehman
Maqsood Ur Rehman
Paeonia emodi has long been used in folk medicine to treat a variety of ailments, including diabetes, skin disorders, dropsy, cuts, wounds, ulcers, fever, and blood disorders, etc., which are generally categorized under the complications of diabetes mellitus. Various species of this genus have also been verified to possess strong anti‐diabetic activity. In this context, the current study was designed to investigate the antidiabetic potential to confirm the purported traditional use of P. emodi . Different solvent fractions of P. emodi , i.e., crude methanolic extract (Pe.Cr), n‐hexane (Pe.Hex), chloroform (Pe.Chf), ethyl acetate (Pe.EtAc), butanol (Pe.Bt) and aqueous (Pe.Aq) were used for in vitro studies against α‐glucosidase, α‐ amylase, dipeptidyl peptidase‐4 (DPP‐4), and protein tyrosine phosphatase 1B (PTP‐1B) using a spectrophotometer and microplate reader. Among all fractions, Pe.Bt had the most prominent activity and was subjected to GC–MS analysis, in vivo anti‐diabetic, pancreas protective, and hepatoprotective studies in alloxan‐induced diabetes rats. The animals administered with alloxan (except group1) having FBGL higher than 220 mg/dL were selected and placed in different groups. The first group, which served as a normal control, received normal saline. The second group received a 5% tween‐80 suspension, which served as diabetic control. The 3rd, 4th and 5th groups were administered Pe.Bt at the doses of 150, 300, and 500 mg/kg body weight, respectively, through oral gavage. Group six received metformin 50 mg/kg and served as the standard group. Fasting Blood glucose level (FBGL) was checked for 21 days. Liver function tests, insulin level, hepatoprotection, and pancreas protection study were investigated. The α‐glucosidase was inhibited effectively by Pe.Bt with an IC 50 value of 626 μg/mL. The antioxidant activities also substantiated the excellent inhibitory potential of Pe.Bt. The IC 50 value of Pe.Bt against DPPH and ABTS was figured out to be 77 and 139 μg/mL, respectively, which was relatively comparable with ascorbic acid. Similarly, Pe.Bt was found active against PTP‐1B and showed a moderate effect against DPP4 with IC 50 of 45.13 and 92.45, respectively. In the time frame of 21 days, the metformin and Pe.Bt significantly decreased FBGL on the 21st day to 108 and 96 mg/dL, respectively. Similarly, rats treated with Pe.Bt (500 mg/kg) significantly lowered the level of alanine transaminase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) and increased total protein level (TP) in comparison with the diabetic control group. The histopathological study revealed that rats treated with Pe.Bt (500 mg/kg) have a remarkable ameliorative effect on liver and pancreas histological architecture as compared to the diabetic control group. The findings of the current investigations indicated that Pe.Bt possesses strong anti‐diabetic, hepatoprotective, anti‐oxidant properties and alleviates alloxan‐induced pancreatic damage in diabetic rats.